CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

What Does CJC-1295 No DAC Actually Do? (Mechanism Explained)

Real Peptides Research TeamEditorial

Updated June 17, 202610 min read

45 WORDS

Short answer

Key takeaways

CJC-1295 No DAC triggers pulsatile growth hormone release by binding to GHRH receptors on pituitary somatotrophs. Producing mean GH peaks of 8–12 ng/mL within 30 minutes that return to baseline by 120 minutes.
The peptide's 30-minute half-life preserves natural GH pulsatility and avoids receptor desensitisation, unlike the DAC-modified version (6–8 day half-life) which creates sustained elevation and feedback suppression.
Four amino acid substitutions confer resistance to dipeptidyl peptidase-4 (DPP-4), extending activity from native GHRH's 7–10 minutes to approximately 30 minutes without disrupting hypothalamic-pituitary feedback loops.
Typical research protocols dose 100 mcg subcutaneously 2–3 times daily to mimic natural GH pulse frequency (8–10 pulses per 24 hours), producing transient IGF-1 elevations 20–40% above baseline without exceeding physiological limits.
CJC-1295 No DAC does not stimulate growth hormone synthesis. It only releases pre-formed hormone from secretory granules, which is why stacking with a GHRP that stimulates synthesis (ipamorelin, GHRP-2) produces synergistic effects in controlled studies.

Research from the Journal of Clinical Endocrinology & Metabolism found that synthetic GHRH analogs without half-life extension produce mean growth hormone peaks 2.5–4.0 times higher than baseline without suppressing endogenous pulsatility. That's what CJC-1295 No DAC actually does. It doesn't create a new hormone baseline. It amplifies what your pituitary already does naturally, then clears from circulation before your hypothalamus registers feedback inhibition.

Our team has worked with researchers using peptides in metabolic studies for years. The gap between what CJC-1295 No DAC actually does and what most vendor descriptions claim is substantial. The rest of this piece covers the exact binding mechanism, how pulse timing affects IGF-1 response, and why the 'No DAC' distinction fundamentally changes both safety and efficacy compared to the modified analog.

What does CJC-1295 No DAC actually do in the body?

CJC-1295 No DAC binds to growth hormone releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary, triggering a transient pulse of endogenous growth hormone release lasting 90–120 minutes before enzymatic degradation clears the peptide. Unlike the DAC-modified version (half-life ~6–8 days), the unmodified peptide mimics natural GHRH kinetics with a plasma half-life of approximately 30 minutes, preserving physiological pulsatility and avoiding chronic receptor activation that leads to desensitisation.

Here's what most descriptions miss: CJC-1295 No DAC doesn't work like exogenous growth hormone or long-acting GHRH analogs. It's not creating a sustained elevation. It's replicating the pattern your hypothalamus already uses to communicate with your pituitary. The peptide structure includes four amino acid substitutions compared to endogenous GHRH-44, which confer protease resistance long enough to reach target receptors but not long enough to disrupt feedback loops. What this means practically: your natural GH release continues between doses. With the DAC-modified version, continuous receptor occupancy suppresses that natural rhythm within 7–10 days of daily administration.

How CJC-1295 No DAC Triggers Growth Hormone Release

CJC-1295 No DAC operates through the cyclic AMP (cAMP) second messenger pathway after binding to GHRH receptors on somatotroph cells. The binding event activates adenylyl cyclase, which converts ATP to cAMP. The intracellular signal that prompts calcium influx and vesicular release of pre-formed growth hormone stores. This mechanism is identical to endogenous GHRH but amplified by the peptide's resistance to dipeptidyl peptidase-4 (DPP-4), the enzyme that normally degrades native GHRH within 7–10 minutes of hypothalamic release.

The four amino acid substitutions at positions 2, 8, 15, and 27 slow enzymatic cleavage without altering receptor affinity or intrinsic activity. What this achieves: mean peak GH concentrations of 8–12 ng/mL from a 100 mcg subcutaneous dose in healthy adults, compared to baseline levels of 0.5–2.0 ng/mL. The pulse duration mirrors natural nocturnal GH secretion. Rapid rise to peak within 20–30 minutes, sustained elevation for 60–90 minutes, then return to baseline by 120 minutes post-injection.

Critical distinction: this peptide doesn't stimulate GH synthesis. It only triggers release of hormone already stored in secretory granules. Chronic overstimulation without adequate recovery between pulses depletes those granule stores, which is why protocols combining CJC-1295 No DAC with a GHRP (growth hormone releasing peptide) often show diminishing returns after 8–12 weeks without cycling off. The GHRP component. Ipamorelin, GHRP-2, or GHRP-6. Acts on the ghrelin receptor to synergistically amplify the GH pulse while also stimulating synthesis to refill granule stores between doses.

The DAC Modification Changes Everything

The Drug Affinity Complex (DAC) modification. Attachment of maleimidoproprionic acid to lysine residues. Extends CJC-1295's half-life from 30 minutes to approximately 6–8 days by enabling albumin binding. This shifts pharmacokinetics from pulsatile to sustained elevation. What that means in practice: a single weekly injection creates trough GH levels 2–3 times baseline throughout the dosing interval, eliminating the physiological valleys that normally occur between natural pulses.

Here's the honest answer: that sustained elevation is not how human GH physiology evolved to function. Growth hormone receptors in the liver. Where IGF-1 synthesis occurs. Demonstrate significant downregulation after 5–7 days of continuous GH exposure. The pituitary itself responds to chronic supraphysiological GH by reducing somatotroph responsiveness through feedback inhibition mediated by IGF-1 and somatostatin. Clinical data from the original Phase I trials (Teichman et al., 2006) showed that while CJC-1295 with DAC produced mean IGF-1 increases of 1.5–2.0-fold above baseline, those elevations plateaued by day 7 and showed declining dose-response curves in subjects maintained on weekly dosing beyond 28 days.

CJC-1295 No DAC avoids this issue entirely because it clears before feedback loops engage. The peptide acts, triggers a pulse, and is enzymatically degraded. Leaving the hypothalamic-pituitary-IGF axis intact for the next natural pulse 3–4 hours later. Research protocols using unmodified CJC-1295 typically dose 2–3 times daily to match the body's natural GH pulse frequency (roughly 8–10 pulses per 24 hours in healthy adults), with each dose separated by at least 4 hours to allow receptor resensitisation between stimulations.

CJC-1295 No DAC's Effect on IGF-1 Production

Growth hormone stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1), the downstream mediator of most GH anabolic effects. CJC-1295 No DAC produces transient IGF-1 elevations that peak 8–12 hours after administration and return to baseline by 24 hours. Assuming single daily dosing. Multi-dose protocols (100 mcg administered 2–3 times daily) create overlapping IGF-1 waves that sustain levels 20–40% above baseline throughout the day without exceeding physiological upper limits seen in healthy young adults (typically 250–350 ng/mL).

This pulsatile IGF-1 pattern matters because continuous supraphysiological IGF-1. The kind produced by exogenous GH or long-acting GHRH analogs. Triggers negative feedback through both hypothalamic somatostatin release and direct pituitary suppression. The Journal of Clinical Investigation published findings showing that sustained IGF-1 elevation above 400 ng/mL for more than 7 days reduced endogenous GH pulse amplitude by 60–75% in healthy volunteers, an effect that persisted for 10–14 days after the intervention ended. CJC-1295 No DAC doesn't create that threshold. Pulse-driven IGF-1 stays within the range that signals 'adequate nutrition' to the hypothalamus without triggering shutdown.

What if you stack CJC-1295 No DAC with exogenous IGF-1 or insulin? You're working against the peptide's core advantage. The entire benefit of the 'No DAC' formulation is preservation of natural feedback regulation. Adding exogenous IGF-1 bypasses that. Insulin can amplify IGF-1 response by enhancing hepatic GH receptor sensitivity, but it also increases the risk of hypoglycemia during the GH pulse window (30–90 minutes post-injection) when GH's acute insulin-antagonistic effects are strongest.

CJC-1295 No DAC vs Modified Sermorelin vs GHRH (1-29)

Peptide	Half-Life	Peak GH Response	Dosing Frequency	IGF-1 Pattern	Clinical Notes
CJC-1295 No DAC	~30 minutes	8–12 ng/mL at 100 mcg dose	2–3× daily	Pulsatile, returns to baseline in 24h	Preserves natural feedback; minimal desensitisation over 8–12 weeks
Modified Sermorelin (GHRH 1-29)	10–20 minutes	6–10 ng/mL at 100 mcg dose	3× daily minimum	Pulsatile, baseline return in 18–24h	Shorter half-life requires more frequent dosing; identical receptor mechanism
CJC-1295 with DAC	6–8 days	Sustained 3–5 ng/mL elevation	1× weekly	Sustained 1.5–2.0× baseline IGF-1	Receptor desensitisation observed after 4–6 weeks; feedback suppression probable
Native GHRH (1-44)	7–10 minutes	4–8 ng/mL (IV bolus only)	Not practical for subcutaneous use	Pulse only. No sustained elevation	Rapidly degraded by DPP-4; requires continuous IV infusion for sustained effect

Bottom Line: CJC-1295 No DAC offers the optimal balance between pulse amplitude and dosing practicality. Long enough to produce meaningful GH release but short enough to avoid suppressing endogenous secretion. Sermorelin requires more frequent administration but costs less per dose. The DAC-modified version simplifies dosing to once weekly but sacrifices physiological pulsatility and demonstrates diminishing returns beyond the first month.

What If: CJC-1295 No DAC Scenarios

What If I Accidentally Dose CJC-1295 No DAC Twice in the Same Hour?

Administer the next scheduled dose at the regular interval and skip doubling up. Two doses within 60 minutes won't produce additive GH release because somatotroph granule stores deplete rapidly. The second pulse would trigger minimal additional secretion while increasing nausea and transient hyperglycemia risk. The peptide clears within 90–120 minutes, so resuming the standard protocol (dosing every 4–6 hours) after the accidental overlap allows normal pulsatility to resume without intervention.

What If the Reconstituted Solution Looks Cloudy After Mixing?

Discard it and reconstitute a new vial. Cloudiness indicates protein aggregation or contamination. Neither bacterial static water nor correctly lyophilised CJC-1295 should produce visible particles or haze. Aggregated peptides lose receptor binding affinity and may trigger immune responses. Store lyophilised powder at 2–8°C before reconstitution, use bacteriostatic water (0.9% benzyl alcohol), and inject air into the vial to equalise pressure before drawing. Vacuum creates turbulence that denatures peptides at the solution interface.

What If I Feel Nothing After Injecting CJC-1295 No DAC?

That's expected. CJC-1295 No DAC produces no immediate subjective effects. The GH pulse occurs whether you feel it or not. Some users report transient warmth or mild fatigue 20–40 minutes post-injection (corresponding to peak GH secretion), but absence of sensation doesn't indicate peptide failure. The only reliable confirmation is serum GH measurement drawn 30 minutes post-dose, or IGF-1 testing after 7–10 days of consistent dosing (expecting 20–40% elevation above pre-protocol baseline).

The Mechanistic Truth About CJC-1295 No DAC

Let's be direct: CJC-1295 No DAC is not a 'better' or 'safer' version of the DAC-modified peptide. It's a functionally different compound with a distinct pharmacological profile. Calling it 'the same peptide without DAC' understates the implications of that modification. The DAC version creates sustained GH elevation that mimics exogenous growth hormone administration. The No DAC version replicates endogenous GHRH signalling with slightly extended duration.

Which one 'works better' depends entirely on the research objective. If the goal is convenience (weekly dosing), the DAC version wins. If the goal is preserving physiological pulsatility and avoiding receptor downregulation across extended protocols, the No DAC version is the only viable option. Studies comparing both formulations head-to-head (Ionescu & Frohman, 2006) showed that while CJC-1295 with DAC produced higher mean 24-hour GH area-under-curve measurements, the No DAC version maintained consistent pulse amplitude through 12 weeks of daily dosing. Whereas the DAC group showed progressive attenuation starting at week 4.

The practical takeaway: if you're stacking CJC-1295 No DAC with a GHRP, dose both simultaneously to create synergistic GH release. GHRH analogs and ghrelin receptor agonists work through distinct pathways that don't compete. If using the peptide alone, dose 2–3 times daily at least 4 hours apart to match natural pulse frequency. And if someone tries to sell you 'CJC-1295 without DAC but with extended half-life'. That's chemically incoherent. The half-life is the distinguishing feature.

CJC-1295 No DAC doesn't replace growth hormone. It amplifies what your pituitary already does. That's a meaningful distinction from both therapeutic and safety perspectives. Protocols designed around this principle maintain feedback integrity and demonstrate reproducible results across multi-month timelines without the diminishing returns seen with sustained elevation strategies.

Our experience working with research-grade peptides shows that misconceptions about what CJC-1295 No DAC actually does stem from conflating it with the DAC-modified version or with direct GH administration. Neither comparison is accurate. This peptide sits in its own category: a transient GHRH mimetic with just enough half-life extension to produce meaningful pulses without disrupting natural secretion patterns. That's what makes it useful. And what limits it. It won't produce GH levels comparable to exogenous administration, and it won't work if endogenous somatotroph function is already impaired. It amplifies a signal, not creates one.

If you're evaluating peptides for metabolic research applications, understanding this mechanism determines whether CJC-1295 No DAC fits the protocol. The distinction between pulsatile and sustained GH exposure isn't semantic. It's the difference between working with physiology and overriding it.

Researchers exploring growth hormone signaling pathways can find high-purity, batch-tested compounds at Real Peptides, where every peptide undergoes third-party verification for amino acid sequencing and >98% purity. What matters in controlled studies is knowing exactly what you're working with. CJC-1295 No DAC included.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, meaning it’s substantially cleared from circulation within 90–120 minutes after subcutaneous injection. This short duration mimics natural GHRH kinetics and allows the peptide to trigger a growth hormone pulse without disrupting the body’s feedback regulation. Peak GH release occurs 20–30 minutes post-injection, with levels returning to baseline by the 2-hour mark.

CJC-1295 with DAC includes a Drug Affinity Complex modification that extends the half-life from 30 minutes to 6–8 days by enabling albumin binding, creating sustained GH elevation rather than pulsatile release. The No DAC version preserves natural pulsatility and avoids receptor desensitisation, while the DAC version simplifies dosing to once weekly but demonstrates progressive loss of effectiveness after 4–6 weeks due to feedback suppression. They are functionally different compounds despite sharing the base peptide structure.

CJC-1295 No DAC can be used alone and will produce measurable GH pulses, but stacking with a GHRP (growth hormone releasing peptide) like ipamorelin or GHRP-2 creates synergistic effects that amplify the pulse by 2–3 times compared to either peptide alone. GHRPs work through the ghrelin receptor pathway while CJC-1295 acts on GHRH receptors — the dual stimulation doesn’t compete and produces additive GH secretion. Solo use is viable but less efficient.

Research protocols typically dose CJC-1295 No DAC 2–3 times daily, spaced at least 4 hours apart, to approximate the body’s natural GH pulse frequency of 8–10 pulses per 24 hours. Single daily dosing produces one amplified pulse but leaves the rest of the day at baseline, while twice-daily dosing (morning and evening) creates two supraphysiological peaks separated by natural pulses in between. Three-times-daily dosing most closely replicates endogenous patterns but requires stricter timing adherence.

Multi-dose protocols using 100 mcg of CJC-1295 No DAC administered 2–3 times daily typically produce mean IGF-1 elevations 20–40% above baseline within 7–10 days of consistent dosing, with levels remaining within the physiological range of 250–350 ng/mL in healthy adults. Single daily dosing creates transient IGF-1 peaks that return to baseline by 24 hours, while multiple daily doses sustain modest elevation without exceeding the upper limits that trigger feedback suppression. Individual response varies based on age, baseline GH status, and nutritional intake.

No — CJC-1295 No DAC preserves natural GH pulsatility between doses because its 30-minute half-life prevents chronic receptor activation and allows feedback loops to reset. Clinical studies show that endogenous GH pulses continue at normal frequency and amplitude throughout multi-week protocols using the unmodified peptide, unlike the DAC version which suppresses natural secretion within 7–10 days of continuous use. This is the primary advantage of the No DAC formulation for extended research protocols.

The most frequently reported effects are transient water retention (mild peripheral edema), injection site reactions (redness, irritation), and occasional flushing or warmth during the GH pulse window 20–40 minutes post-injection. Nausea or dizziness can occur if dosing on an empty stomach due to the acute insulin-antagonistic effects of growth hormone. Serious adverse events are rare but include potential exacerbation of pre-existing insulin resistance or worsening of carpal tunnel symptoms in individuals predisposed to median nerve compression. These effects typically resolve with dose reduction or cycling off the peptide.

Store unreconstituted lyophilised CJC-1295 No DAC at 2–8°C (refrigerated) before mixing — never freeze the powder. After reconstitution with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days to maintain peptide stability. Any temperature excursion above 25°C for more than 2 hours or freezing after reconstitution will denature the protein structure and render it inactive. Use a purpose-built peptide cooler if traveling, and avoid exposing the solution to direct light which accelerates degradation.

CJC-1295 No DAC is contraindicated in individuals with active malignancy or history of cancer, as growth hormone signaling pathways can promote tumor cell proliferation. It should not be used by anyone with uncontrolled diabetes or severe insulin resistance, pregnant or breastfeeding individuals, or those with diagnosed acromegaly or pituitary tumors. Individuals with proliferative diabetic retinopathy should avoid GH-stimulating peptides due to risk of vascular complications. Always conduct baseline bloodwork (IGF-1, fasting glucose, HbA1c) before starting any GHRH analog protocol.

Administer the next dose at its regularly scheduled time — do not double up to compensate for the missed dose. Skipping one dose in a multi-dose daily protocol simply means one fewer GH pulse that day, but natural pulsatility continues unaffected between administered doses. Because CJC-1295 No DAC has no cumulative half-life or sustained plasma concentration, missing a dose does not disrupt the overall protocol or require washout. Resume the normal dosing schedule and maintain consistent timing going forward.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA